Becton, Dickinson and Company (BDX) Competitors

DexCom (NASDAQ:DXCM) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.

Is DXCM or BDX more profitable?

DexCom has a net margin of 16.82% compared to DexCom's net margin of 6.76%. Becton, Dickinson and Company's return on equity of 31.01% beat DexCom's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	16.82%	31.01%	10.29%
Becton, Dickinson and Company	6.76%	13.90%	6.73%

Which has more risk and volatility, DXCM or BDX?

DexCom has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.

Does the media prefer DXCM or BDX?

In the previous week, Becton, Dickinson and Company had 9 more articles in the media than DexCom. MarketBeat recorded 22 mentions for Becton, Dickinson and Company and 13 mentions for DexCom. Becton, Dickinson and Company's average media sentiment score of 1.04 beat DexCom's score of 0.68 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, DXCM or BDX?

Becton, Dickinson and Company has higher revenue and earnings than DexCom. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$3.80B	13.33	$541.50M	$1.55	82.21
Becton, Dickinson and Company	$19.72B	3.42	$1.48B	$4.54	51.45

Does the MarketBeat Community prefer DXCM or BDX?

DexCom received 361 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 71.95% of users gave DexCom an outperform vote while only 62.29% of users gave Becton, Dickinson and Company an outperform vote.

Company	Underperform	Outperform
DexCom	Outperform Votes 949 71.95%	Underperform Votes 370 28.05%
Becton, Dickinson and Company	Outperform Votes 588 62.29%	Underperform Votes 356 37.71%

Do insiders and institutionals hold more shares of DXCM or BDX?

97.8% of DexCom shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of DexCom shares are held by insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts rate DXCM or BDX?

DexCom presently has a consensus target price of $141.67, suggesting a potential upside of 11.18%. Becton, Dickinson and Company has a consensus target price of $281.40, suggesting a potential upside of 20.47%. Given DexCom's higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Becton, Dickinson and Company	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

DexCom beats Becton, Dickinson and Company on 14 of the 19 factors compared between the two stocks.